Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-γ production in the presence of Toxoplasma gondii antigens

Journal of Infectious Diseases

Volumn 183, Issue 11, 2001, Pages 1586-1591

  Fournier, S ^a   Rabian, C ^a   Alberti, C ^a   Carmagnat, M V ^a   Garin, J F ^a   Charron, D ^a   Derouin, F ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; PARASITE ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD DONOR; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROPREVALENCE; SEX RATIO; TOXOPLASMA GONDII; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTI-HIV AGENTS; ANTIGENS, PROTOZOAN; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; TOXOPLASMA;

EID: 0035370289     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320706     Document Type: Article

References (22)

1. Luft B, Hafner R, Korzun A, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993; 329:995-1000.
2. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The Changes in Opportunistic Prophylaxis Study. J Infect Dis 2000; 181:1635-42.
3. Furrer H, Opravil M, Bernasconi E. Telenti A, Egger M, for the Swiss HIV Cohort Study. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Lancet 2000; 355:2217-8.
4. US Public Health Service (USPHS)/Infectious Diseases Society of America (IDSA). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with HIV; part II. prevention of the first episode of disease. Am Fam Physician 2000; 61:441-2, 445-9, 453-4 passim.
5. + T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 1992; 149:175-80.
6. Belanger F, Derouin F, Grangeot-Keros L, Meyer L, and the HEMOCO and SEROCO study group. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. Clin Infect Dis 1999; 28:575-81.
7. Murray H, Hillman J, Rubin B, et al. Patients at risk for AIDS-related opportunistic infections: clinical manifestations and impaired gamma interferon production. N Engl J Med 1985; 313:1504-10.
8. Derouin F, Rabian-Herzog C, Ballet J. Impaired in vitro lymphocyte response to Toxoplasma antigen in HIV1 infected patients. J Clin Lab Immunol 1989; 28:179-82.
9. Suzuki Y, Orellana M, Schreiber R, Remington J. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988; 240:516-8.
10. Beaman M, Wong S, Remington J. Cytokines, toxoplasma and intracellular parasitism. Immunol Rev 1992; 127:97-117.
11. Ullum H, Cozzi Lepri A, Bendtzen K, et al. Low production of interferon γ is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses 1997; 13:1039-46.
12. Li T, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Longlasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
13. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Med 1998; 4:953-6.
14. Wendland T, Furrer H, Vernazza P. et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 1999; 13:1857-62.
15. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
16. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9:811-8.
17. Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group. Lancet 1998; 352:1725-30.
18. Schneider M, Borleffs J, Stolk R, Jaspers C, Hoepelman A. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353:201-3.
19. El-Sadr W, Burman W, Bjorling Grant L, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000; 342:1085-92.
20. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.
21. Derouin F, Leport C, Pueyo S, et al. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. AIDS 1996; 10:1521-7.
22. Connick E, Lederman M, Kotzin B. et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181:358-63.